OGN Stock Analysis: Organon | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 3.648m USD | 12M Return: 86.5% | US68622V1061 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 33.4M
EPS Trend: -91.7%
Qual. Beats: 0
Rev. Trend: -78.6%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 5.4 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Organon & Co. (NYSE: OGN) is a global womens health-focused pharmaceutical company headquartered in Jersey City, New Jersey, and founded in 1923. The company develops and markets prescription therapies and medical devices across more than 100 countries, with a core franchise spanning contraception, fertility, and womens health products such as Nexplanon, NuvaRing, and Jada. Beyond womens health, Organon operates three additional segments: biosimilars (including immunology and oncology products like Brenzys, Renflexis, and Ontruzant), established brands covering cholesterol, hypertension, respiratory, dermatology, bone health, and pain management (e.g., Zetia, Cozaar, Singulair, Fosamax), and select other therapies such as Proscar and Propecia. Its products are distributed to drug wholesalers, retailers, hospitals, clinics, government agencies, HMOs, and pharmacy benefit managers.
Organon was spun off from Merck & Co. in 2021 as a publicly traded mid-cap pharmaceutical company, inheriting a portfolio of established off-patent and biosimilar medicines rather than pursuing innovative drug discovery. This business model emphasizes commercial scale, lifecycle management of mature products, and expansion into biosimilars and womens health, which is a comparatively underserved therapeutic category within the broader pharmaceutical sector.
- Nexplanon revenue growth anchors womens health segment
- Biosimilars face intensifying pricing pressure from new market entrants
- International currency headwinds pressure reported revenue growth
| Net Income: 213.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.86 > 1.0 |
| NWC/Revenue: 44.55% < 20% (prev 32.07%; Δ 12.47% < -1%) |
| CFO/TA 0.06 > 3% & CFO 843.0m > Net Income 213.0m |
| Net Debt (7.10b) to EBITDA (1.29b): 5.49 < 3 |
| Current Ratio: 2.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (272.4m) vs 12m ago 4.50% < -2% |
| Gross Margin: 53.42% > 18% (prev 55.04%; Δ -1.62% > 0.5%) |
| Asset Turnover: 45.26% > 50% (prev 46.49%; Δ -1.24% > 0%) |
| Interest Coverage Ratio: 2.13 > 6 (EBIT TTM 949.0m / Interest Expense TTM 446.0m) |
| A: 0.20 (Total Current Assets 5.37b - Total Current Liabilities 2.65b) / Total Assets 13.4b |
| B: 0.11 (Retained Earnings 1.51b / Total Assets 13.4b) |
| C: 0.07 (EBIT TTM 949.0m / Avg Total Assets 13.5b) |
| D: 0.10 (Book Value of Equity 1.19b / Total Liabilities 12.2b) |
| Altman-Z'' = 2.27 = BBB |
| DSRI: 1.01 (Receivables 1.48b/1.52b, Revenue 6.10b/6.30b) |
| GMI: 1.03 (GM 55.04% / 53.42%) |
| AQI: 0.90 (AQ_t 0.50 / AQ_t-1 0.56) |
| SGI: 0.97 (Revenue 6.10b / 6.30b) |
| TATA: -0.05 (NI 213.0m - CFO 843.0m) / TA 13.4b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of November 12, 2026, the stock is trading at USD 13.89 with a total of 1,870,557 shares traded. Over the past week, the price has changed by +0.58%, over one month by +1.02%, over three months by +2.05% and over the past year by +86.48%.
Current recommended Stop Loss: 13.80 (which is 0.6% or 1.8 ATR below the current price).
Organon has received a consensus analysts rating of 2.75. Therefore, it is recommended to hold OGN.
- StrongBuy: 0
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 10.3 | -25.6% |
P/E Trailing = 17.8077
P/E Forward = 5.0891
P/S = 0.5981
P/B = 3.0489
Revenue TTM = 6.10b USD
EBIT TTM = 949.0m USD
EBITDA TTM = 1.29b USD
Long Term Debt = 8.48b USD (from longTermDebt, last quarter)
Short Term Debt = 69.0m USD (from shortTermDebt, last quarter)
Debt = 8.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.10b USD (calculated: Debt 8.55b - CCE 1.46b)
Enterprise Value = 10.7b USD (3.65b + Debt 8.55b - CCE 1.46b)
Interest Coverage Ratio = 2.13 (Ebit TTM 949.0m / Interest Expense TTM 446.0m)
EV/FCF = 15.92x (Enterprise Value 10.7b / FCF TTM 675.0m)
FCF Yield = 6.28% (FCF TTM 675.0m / Enterprise Value 10.7b)
FCF Margin = 11.07% (FCF TTM 675.0m / Revenue TTM 6.10b)
Net Margin = 3.49% (Net Income TTM 213.0m / Revenue TTM 6.10b)
Gross Margin = 53.42% ((Revenue TTM 6.10b - Cost of Revenue TTM 2.84b) / Revenue TTM)
Gross Margin QoQ = 55.21% (prev 54.36%)
Tobins Q-Ratio = 0.80 (Enterprise Value 10.7b / Total Assets 13.4b)
Interest Expense / Debt = 5.21% (Interest Expense 446.0m / Debt 8.55b)
Taxrate = 35.69% (91.0m / 255.0m)
NOPAT = 610.3m (EBIT 949.0m * (1 - 35.69%))
Current Ratio = 2.02 (Total Current Assets 5.37b / Total Current Liabilities 2.65b)
Debt / Equity = 7.17 (Debt 8.55b / totalStockholderEquity, last quarter 1.19b)
Debt / EBITDA = 5.49 (Net Debt 7.10b / EBITDA 1.29b)
Debt / FCF = 10.52 (Net Debt 7.10b / FCF TTM 675.0m)
Total Stockholder Equity = 963.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.58% (Net Income 213.0m / Total Assets 13.4b)
RoE = 22.11% (Net Income TTM 213.0m / Total Stockholder Equity 963.5m)
RoCE = 10.04% (EBIT 949.0m / Capital Employed (Equity 963.5m + L.T.Debt 8.48b))
RoIC = 5.81% (NOPAT 610.3m / Invested Capital 10.5b)
WACC = 5.07% (E(3.65b)/V(12.2b) * Re(9.11%) + D(8.55b)/V(12.2b) * Rd(5.21%) * (1-Tc(0.36)))
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 81.09 | Cagr: 2.34%
[DCF] Terminal Value 77.97% ; FCFF base≈631.4m ; Y1≈723.8m ; Y5≈1.07b
[DCF] Fair Price = 34.01 (EV 16.0b - Net Debt 7.10b = Equity 8.93b / Shares 262.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -91.65 | EPS CAGR: -11.02% | SUE: -0.75 | # QB: 0
Revenue Correlation: -78.63 | Revenue CAGR: -1.41% | SUE: -0.05 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.92 | Chg30d=+4.99% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=3.44 | Chg30d=+0.09% | Revisions=-25% | GrowthEPS=-6.1% | GrowthRev=-0.9%
EPS next Year (2027-12-31): EPS=3.65 | Chg30d=+0.90% | Revisions=-25% | GrowthEPS=+6.2% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: -50% (up=0, down=3)